Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01813838Phase 1Terminated

GFM-Acadesine: A Phase I-II Trial of Acadesine

Role: collaborator

NCT01428726Phase 2Completed

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Role: collaborator

NCT01316406Phase 2Completed

Safety and Efficacy Placebo Controlled Study of ATH008 Cream in PPES Patients Secondary to Capecitabine

Role: lead

NCT00559624Phase 1Completed

Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL Patients

Role: lead

All 4 trials loaded